Counting the costs of drug-related adverse events

PharmacoEconomics

Volumn 15, Issue 5, 1999, Pages 445-458

  White, T Jeffrey ^a   Arakelian, Annet ^b   Rho, Jay P ^b  

^a Univ of S CA Sch of Social Wk   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; CONTRAST MEDIUM; NEUROMUSCULAR BLOCKING AGENT; PSYCHOTROPIC AGENT; RESPIRATORY TRACT AGENT;

ADVERSE DRUG REACTION; COST CONTROL; COST UTILITY ANALYSIS; DRUG MONITORING; HEALTH CARE COST; HUMAN; MORTALITY; PHARMACY BENEFIT MANAGER; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW;

ANIMALS; COST OF ILLNESS; ECONOMICS, PHARMACEUTICAL; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 0032899232     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199915050-00003     Document Type: Review

References (55)

1. Johnson JA, Bootman JL. Drug-related morbidity and mortality. Arch Intern Med 1995; 155: 1949-56
2. Bates DW, Leape LL, Petrychi S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 1993; 8: 289-94
3. World Health Organization. International Drug Monitoring: The Role of the Hospital. Geneva, Switzerland: World Health Organization; 1966. Technical Report Series No. 425
4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5
5. Bates DW. Drugs and adverse drug reactions - How worried should we be? JAMA 1998; 279: 1216-7
6. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: Implications for prevention. JAMA 1995; 274: 29-34
7. OBrien BJ, Novosel S, Torrance G, et al. Assessing the economic value of a new antidepressant: A willingness to pay approach. Pharmacoeconomics 1995; 8: 34-45
8. Gold MR, Seigel JE, Russell LB, et al. Cost-effectiveness analysis as a guide to resource allocation in health: Roles and limitations. In: Cost-Effectiveness in Health and Medicine. New York (NY): Oxford University Press, 1996: 3-24
9. Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996 10: 460-6
10. Moore TJ, Psaty BM, et al. Commentary: Time to act on drug safety. JAMA 1998; 279: 1571-3
11. Evans RS, Pestotnik SL, Classen DC, et al. Preventing adverse drug events in hospitalized patients. Ann Pharmacother 1994; 28: 523-7
12. Classen DC, Pestonik SL, Evans RS, et al. Adverse drug events in hospitalized patients: Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301-6
13. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997; 277: 307-11
14. Cullen DJ, Sweitzer BJ, Bates DW, et al. Preventable adverse drug events in hospitalized patients: A comparative study of intensive care and general care units. Crit Care Med 1997; 25: 1289-97
15. Dartnell JGA, Anderson RP, Chohan V, et al. Hospitalization for adverse events related to drug therapy: Incidence, avoidability and costs. Med J Austr 1996; 659-62
16. Schneider PJ, Gift MG, Lee YP, et al. Cost of medication-related problems at a university hospital. Am J Health Syst Pharm 1995; 2415-8
17. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993; 27: 832-40
18. McGoldrick MD, Bailie GR. Nonnarcotic analgesics: Prevalence and estimated economic impact of toxicities. Ann Pharmacother 1997; 31: 221-7
19. Bjorkman DJ. Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury. Am J Med 1996; 101: 25S-32S
20. Johnson RE, Hornbrook MC, Hooker RS, et al. Analysis of the costs of NSAID-associated gastropathy: Experience in a US health maintenance organisation. Pharmacoeconomics 1997; 12: 76-88
21. Bloor K, Maynard A. Is there scope for improving the cost-effective prescribing of nonsteroidal anti-inflammatory drugs? Pharmacoeconomics 1996; 9: 484-96
22. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with non-steroidal antiinflammatory drugs. N Engl J Med 1998; 338: 727-34
23. Gabriel SE, Campiod ME, OFallon WM. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994; 37: 333-41
24. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking non-steroidal anti-inflammatory drugs. Arch Intern Med 1989; 149: 2061-5
25. Smith KM, McAdams JW, Frenia ML, et al. Drug-related problems in emergency department patients. Am J Health Syst Pharm 1997; 54: 295-8
26. Holloway JJ, Smith CR, Moore RD, et al. Comparative cost-effectiveness of gentamicin and tobramycin. Ann Intern Med 1984; 101: 764-9
27. Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980; 302: 1106-9
28. Eisenberg JM, Koffer H, Glick HA, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987; 107: 900-
29. Zaske DE. Aminoglycosides. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied Pharmacokinetics. Vancouver: Applied Therapeutics Inc., 1992
30. Davey P, Hernanz C, Lynch W, et al. Human and non-financial costs of hospital-acquired infection. J Hosp Infect 1991; 18 Suppl. A: 79-84
31. Garrelts JC, Horst WD, Silkey B, et al. A pharmacoeconomic model to evaluate antibiotic costs. Pharmacotherapy 1994; 14: 438-5
32. Riley TV, Codde JP Rousse IL. Increased length of hospital stay due to Clostridium difficile associated diarrhoea. Lancet 1995; 345: 455-6
33. Riley TV. Antibiotic-associated diarrhea: A costly problem. Pharmacoeconomics 1996; 10 (1): 1-3
34. Eckman MH, Levine HJ, Pauker SG. Making decisions about antithrombotic therapy in heart disease: Decision analytic and cost-effectiveness issues. Chest 1995; 108: 457S-70S
35. Lousberg TR, Witt DM, Beal DG, et al. Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch Intern Med 1998; 158: 528-34
36. Hull RD, Raskob GE, Rosenblooom D, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin: An economic perspective. Arch Intern Med 1997; 157: 289-94
37. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation: An economic perspective. Arch Intern Med 1997; 157: 298-303
38. OBrien BJ, Rusthoven J, Rocchi A, et al. Impact of chemotherapy-associated nausea and vomiting on patients functional status and on costs: Survey of five Canadian centres. Can Med Assoc J 1993; 149: 296-302
39. Ballatori E, Roila F, Berto P, et al. Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: A hospital perspective from Italy. Pharmacoeconomics 1994; 5: 227-37
40. Jones AL, Lee GJ, Bosanquet N. The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis. Eur J Cancer 1993; 29A: 51-6
41. Zbrozek AS, Cantor SB, Cardenas MR et al. Pharmacoeconomic analysis of ondansetron versus metoclopramide of cisplatin-induced nausea and vomiting. Am J Hosp Pharm 1994; 51: 1555-63
42. Dranistaris G, Tran TM. Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy. Eur J Cancer 1995; 31A: 2174-80
43. Ghandi AJ, Vlasses PH, Morton DJ, et al. Economic impact of digoxin toxicity. Pharmacoeconomics 1997; 12: 175-81
44. Mauskofp JA, Wenger TL. Cost-effectiveness analysis of the use of digoxin immune Fob (ovine) for treatment of digoxin toxicity. Am J Cardiol 1991; 68: 1709-14
45. Grant KL, Camamo JM. Adverse events and cost savings three years after implementation of guidelines for outpatient contrast-agent use. Am J Health Syst Pharm 1997; 54: 1395-401
46. Rudis MI, Guslits BJ, Peterson EL, et al. Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit. Crit Care Med 1996; 24: 1749-56
47. Depression Guideline Panel. Depression in Primary Care Volume 2: Treatment of Major Depression. Rockville, MD: US Department of Health and Human Services, US Public Health Service, Agency for Health Care Policy and Research; April 1993. AHCPR Publication No. 93-0552, Clinical Practice Guidelines No. 5
48. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54: 11: 405-18
49. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of anti-depressant drug therapy failure: A study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990; 51: 60-9
50. Thompson D, Buesching D, Gregor KJ, et al. Patterns of anti-depressant use and their relation to costs of care. Am J Manage Care 1996; 2: 1239-46
51. Terkelsen KG, Meninkoff A. Measuring the costs of schizophrenia: Implications for the post-institutional era in the US. Pharmacoeconomics 1995; 8 (3): 199-222
52. Knapp M, Kavanagh S. Economic outcomes and costs in the treatment of schizophrenia. Clin Ther 1997; 19: 128-38
53. Paloucek FP, Rodvold KA. Evaluation of theophylline overdoses and toxicities. Ann Emerg Med 1998; 17: 135-44
54. Hamilton RA, Gordon T. Incidence and cost of hospital admissions secondary to drug interactions involving theophylline. Ann Pharmacother 1992; 26: 1507-1
55. Hamilton RA. Economic costs of theophylline toxicity. Pharmacoeconomics 1994; 5: 177-9